IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2013 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris Plains, NJ, May 8, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the ...
IMMUNOMEDICS ANNOUNCES THREE NEW PATENT AWARDS -- The Company Ranked Tenth in the World for US Patents in Biotechnology/Pharmaceuticals -- Morris Plains, NJ, May 7, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical ...
Immunomedics Inc. (NASDAQ: IMMU) is on the radar screen as a possible option trade candidate. Immunomedics is a biopharmaceutical company engaged in the research, development, manufacture and marketing of monoclonal, antibody-based products ...
Immunomedics, Inc. (NASDAQ:IMMU) traded 6.12% higher to close last trading session at $2.95, extending three-day winning streak after its 3Q results topped expectations.
MORRIS PLAINS, Apr 25, 2013 (GLOBE NEWSWIRE via COMTEX) -- Immunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, ...
Immunomedics (NASDAQ:IMMU) will report earnings after markets close on Wednesday, May 8th. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products.
Immunomedics, Inc. (NASDAQ: IMMU) is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
Immunomedics, Inc. (NASDAQ:IMMU) is working with the Karolinska Institutet to develop a new class of drugs designed to vanquish the virus, not just control it.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.